Mon panier

Biotinylated Human CD20 / MS4A1 Full Length Protein, His,Avitag™ (Nanodisc)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
CD0-H82E3-20ug
$1955.00
CD0-H82E3-100ug
$6460.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Application

    1. Cell based assay (FACS or functional assay)
    2. Affinity testing (SPR / BLI)
    3. Screening (ELISA)
  • Synonyms

    MS4A1, CD20, MS4A-1

  • Source

    Nanodisc Biotinylated Human CD20 Full Length, His,Avitag (CD0-H82E3) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).

    Predicted N-terminus: Met 1

    Request for sequence
  • Molecular Characterization

    CD20 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 36.9 kDa.

    *The isotype control of empty/mock nanodisc (Cat. No. APO-H81Q5) is sold separately and not included in protein, you can follow the link for product information.

    1. Structure

      Nanodisc membrane protein is wrapped by a synthetic phospholipid bilayer membrane structure, composed of membrane scaffold proteins (MSPs) and phospholipids.

    2. Synthesis Process

      Nanodisc reconstitution is a self-assembly process that starts from purified, detergent-solubilized membrane proteins and reconstitutes them into synthetic phospholipid bilayers stabilized by MSP1D1 membrane scaffold protein. This creates a stable, detergent-free environment that preserves native conformation and biological activity, with excellent homogeneity and full compatibility with cell-based assays such as FACS and binding assays in antibody discovery and screening (ELISA),etc.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Formulation

    Supplied as 0.2 μm filtered solution in 20 mM HEPES, 150 mM NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Shipping and Storage

    This product is supplied and shipped on dry ice.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 3 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • Bioactivity-ELISA

     CD20 ELISA

    Immobilized Rituximab biosimilar (Cat. No. CD0-M36) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CD20 Full Length, His,Avitag (Cat. No. CD0-H82E3) with a linear range of 0.6-10 ng/mL (QC tested).

    Protocol
  •  CD20 ELISA

    Immobilized Ofatumumab biosimilar at 5 μg/mL (100 μL/well) can bind Biotinylated Human CD20 Full Length, His,Avitag (Cat. No. CD0-H82E3) with a linear range of 2-39 ng/mL (QC tested).

    Protocol
  • Bioactivity-TR-FRET

     CD20 TR-FRET

    In this TR-FRET assay, Streptavidin Protein Europium chelate (for TR-FRET) (Cat. No. FRT-TD09) is used as the Donor and Monoclonal Anti-Human IgG Antibody FA-Labeled (for TR-FRET) (Cat. No. FRT-TA02) is used as the Acceptor. Biotinylated Human CD20 Full Length, His,Avitag (Cat. No. CD0-H82E3), at 1.5 ng/well, can bind to the Glofitamab with a linear detection range of 16-0.008 μg/mL (Routinely tested).

  • Bioactivity-SPR

     CD20 SPR

    Biotinylated Human CD20 Full Length, His,Avitag (Cat. No. CD0-H82E3) immobilized on SA Chip can bind Rituximab biosimilar (Cat. No. CD0-M36) with an affinity constant of 492 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol
  • Bioactivity-BLI

     CD20 BLI

    Loaded Rituximab on Protein A Biosensor, can bind with Biotinylated Human CD20 Full Length, His,Avitag (Cat. No. CD0-H82E3) an affinity constant of 31.3 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol
  • Bioactivity-FACS

     CD20 FACS

    2e5 of anti-CD20 CAR-293 cells were stained with 100 μL of 3 μg/mL of Biotinylated Human CD20 Full Length, His,Avitag (Cat. No. CD0-H82E3) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (QC tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

A B-lymphocyte surface antigen expressed from pre-B to mature B cells, but absent on plasma cells. It functions as a calcium channel and is a validated immunotherapy target, famously exploited by rituximab for treating B-cell malignancies and autoimmune disorders.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    B-lymphocyte antigen CD20

  • Catégorie:

  • Nombre de médicaments répertoriés:

    35 Détails

  • Nombre de médicaments cliniques:

    132 Détails

  • Étape de développement la plus élevée:

    Approved

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte